Company intelligence / Profile preview

Spago Nanomedical AB

Ownership: Private
Employees: ~12
Development stage: Phase 1

Overview

The company has two main programs: SpagoPix (SN132D) has shown good contrast in breast tumors, liver, and pancreas in initial clinical data without compromising safety. Tumorad (177Lu-SN201) is in Phase I/IIa with positive safety data from the first three treated patients as reported by an independent Data Monitoring Committee in Q3 2024.

Therapeutic areas: Oncology
Modalities: Polymeric nanoparticlesRadiopharmaceuticals
Industry: Biotech

Drug pipeline

2 assets

pegfosimer manganese

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Spago Nanomedical AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spago Nanomedical AB.

Explore the full profile